Vera Nies 

Programme Manager, Lygature

Dr. Vera Nies is an internationally oriented and experienced Programme Manager at Foundation Lygature. Lygature is a not-for-profit foundation that focusses on setting up and managing public-private partnerships, with the ultimate goal to make a long-lasting beneficial impact to the health of all.

Vera was originally trained as a Medical Biologist (Radboud University Nijmegen). She subsequently obtained a PhD in the field of Molecular Mechanisms of Health and Disease (University of Groningen). Vera gained experience in the pharmaceutical industry working as a Regulatory Affairs Manager at Novartis. She joined Lygature as Programme Manager in 2018. Since then, she has been involved in several projects such as RADAR-AD, the European Lead Factory, and a project on Pandemic Preparedness. Nowadays, she combines experience in setting up and leading multi-stakeholder partnerships with expertise in regulatory affairs and patient & public involvement (PPI). She is leading the programme management for ILLUMINATE, an IHI funded partnership aiming to improve theranostics for prostate cancer treatment. In addition, Vera is also co-lead of Lygature’s PPI team, and involved in the recruitment of new opportunities for collaborations (so please approach her if you are keen to explore novel collaborations).

Presentation: The power of ILLUMINATE: A unique approach to improve theranostic options for prostate cancer patients.

Selective targeting of therapy with antibody-radioisotope combinations have led to major advances in treating advanced cancers, such as castrate resistant prostate cancer (CRPC). Prostate cancer is the most prevalent non-cutaneous cancer amongst men in Europe, and the leading cause of death in a quarter of the world’s countries [1][2]. Lutetium-177-prostate-specific membrane antigen (Lu-177-PSMA) is a targeted therapy recently approved for treatment of metastasized prostate cancer (MPC).

Adding Lu-177-PSMA to standard care significantly improves survival of MPC patients [3]. Despite the success of Lu-177-treatment, around 30% of patients do not benefit from the treatment, but do suffer from the side-effects [3][4]. Better assessment and prediction of treatment response could hence significantly improve the treatment plan of MPC patients.

The higher use of Lu-177-based therapies has resulted in an increased demand for this isotope. Manufacturing-related hurdles (such as low number of suppliers, challenges in the manufacturing process, scarcity of the starting material, and the dependency on non-EU countries for raw materials [5]) pose serious challenges to the availability of radioisotope-based therapies. Improved manufacturing of Lu-177 could reduce the risks of shortages, and better availability of treatment options.

Contact           

Connect                   

Veerstraat 27
1211 HJ Hilversum

Chamber of Commerce: 32110979
VAT no: NL8184.34.491.B01
         
 
 

                                    


Register now

© Copyright 2023 by Hyphen Projects | All rights reserved